| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pectins | 11 | 2023 | 27 | 5.140 |
Why?
|
| Pleura | 10 | 2024 | 244 | 5.120 |
Why?
|
| Pneumonectomy | 54 | 2023 | 1118 | 4.790 |
Why?
|
| Lung | 52 | 2024 | 9979 | 3.260 |
Why?
|
| Microcirculation | 20 | 2022 | 1280 | 2.670 |
Why?
|
| Neovascularization, Physiologic | 15 | 2023 | 1347 | 2.650 |
Why?
|
| Pulmonary Alveoli | 9 | 2017 | 651 | 1.940 |
Why?
|
| Capillaries | 8 | 2014 | 755 | 1.490 |
Why?
|
| Tropoelastin | 2 | 2023 | 28 | 1.450 |
Why?
|
| Regeneration | 11 | 2015 | 1505 | 1.430 |
Why?
|
| Neovascularization, Pathologic | 11 | 2024 | 2635 | 1.430 |
Why?
|
| Chorioallantoic Membrane | 2 | 2023 | 50 | 1.340 |
Why?
|
| Tissue Adhesives | 3 | 2020 | 173 | 1.300 |
Why?
|
| Microscopy, Electron, Scanning | 18 | 2019 | 944 | 1.250 |
Why?
|
| Lung Injury | 4 | 2023 | 422 | 1.200 |
Why?
|
| Blood Vessels | 7 | 2017 | 1111 | 1.120 |
Why?
|
| Epithelium | 4 | 2020 | 1603 | 1.050 |
Why?
|
| Microvessels | 6 | 2017 | 580 | 1.020 |
Why?
|
| Colitis | 8 | 2013 | 1234 | 1.000 |
Why?
|
| Lymphocytes | 17 | 2009 | 2603 | 0.970 |
Why?
|
| Regional Blood Flow | 10 | 2014 | 1498 | 0.970 |
Why?
|
| Glycocalyx | 3 | 2023 | 97 | 0.870 |
Why?
|
| Epithelial Cells | 5 | 2024 | 3666 | 0.870 |
Why?
|
| Sheep | 24 | 2011 | 1436 | 0.810 |
Why?
|
| Animals | 107 | 2024 | 168083 | 0.800 |
Why?
|
| Flow Cytometry | 20 | 2013 | 5870 | 0.780 |
Why?
|
| Respiratory Mechanics | 8 | 2018 | 699 | 0.770 |
Why?
|
| Colon | 6 | 2013 | 1791 | 0.760 |
Why?
|
| Stress, Mechanical | 11 | 2017 | 1674 | 0.760 |
Why?
|
| Endothelial Cells | 6 | 2022 | 3550 | 0.740 |
Why?
|
| Membranes, Artificial | 2 | 2020 | 366 | 0.720 |
Why?
|
| Corrosion Casting | 9 | 2022 | 15 | 0.710 |
Why?
|
| Mice | 66 | 2023 | 81324 | 0.670 |
Why?
|
| Hybridomas | 9 | 2009 | 442 | 0.670 |
Why?
|
| Citrus | 1 | 2019 | 49 | 0.670 |
Why?
|
| Antigens, Surface | 20 | 2002 | 1607 | 0.660 |
Why?
|
| Biopolymers | 1 | 2020 | 183 | 0.660 |
Why?
|
| Mice, Inbred C57BL | 27 | 2018 | 22129 | 0.650 |
Why?
|
| Microscopy, Video | 7 | 2014 | 241 | 0.630 |
Why?
|
| Myofibroblasts | 2 | 2019 | 223 | 0.630 |
Why?
|
| Mice, Inbred BALB C | 22 | 2013 | 6198 | 0.610 |
Why?
|
| Lung Neoplasms | 39 | 2020 | 13382 | 0.610 |
Why?
|
| Acoustics | 1 | 2019 | 242 | 0.600 |
Why?
|
| Airway Resistance | 3 | 2017 | 405 | 0.590 |
Why?
|
| Microscopy, Fluorescence | 7 | 2017 | 2637 | 0.580 |
Why?
|
| Lymphoid Tissue | 2 | 2009 | 444 | 0.580 |
Why?
|
| Polysaccharides | 2 | 2020 | 1014 | 0.550 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 367 | 0.550 |
Why?
|
| Water | 2 | 2020 | 1410 | 0.550 |
Why?
|
| Pulmonary Emphysema | 10 | 2007 | 683 | 0.550 |
Why?
|
| Oxazolone | 5 | 2003 | 61 | 0.550 |
Why?
|
| Microspheres | 5 | 2009 | 783 | 0.530 |
Why?
|
| Endothelium, Vascular | 14 | 2020 | 4421 | 0.520 |
Why?
|
| Parabiosis | 2 | 2013 | 64 | 0.500 |
Why?
|
| Blood Circulation | 2 | 2009 | 248 | 0.500 |
Why?
|
| Pulmonary Circulation | 4 | 2022 | 737 | 0.500 |
Why?
|
| Lung Transplantation | 11 | 2017 | 1307 | 0.490 |
Why?
|
| Lymph | 4 | 2002 | 77 | 0.480 |
Why?
|
| Ischemia | 2 | 2022 | 1889 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 35 | 2011 | 9185 | 0.470 |
Why?
|
| Lung Compliance | 2 | 2012 | 200 | 0.470 |
Why?
|
| T-Lymphocytes, Cytotoxic | 16 | 1996 | 1782 | 0.470 |
Why?
|
| Pneumothorax | 1 | 2017 | 386 | 0.460 |
Why?
|
| Melitten | 2 | 2005 | 13 | 0.460 |
Why?
|
| Microscopy, Electron, Transmission | 5 | 2020 | 696 | 0.460 |
Why?
|
| Proteoglycans | 1 | 2017 | 803 | 0.450 |
Why?
|
| Skin | 9 | 2011 | 4473 | 0.450 |
Why?
|
| Elastin | 1 | 2015 | 298 | 0.450 |
Why?
|
| Intestinal Mucosa | 7 | 2013 | 3030 | 0.440 |
Why?
|
| Fluorescent Dyes | 7 | 2010 | 1902 | 0.440 |
Why?
|
| Butyrates | 4 | 2006 | 169 | 0.430 |
Why?
|
| Computational Biology | 4 | 2009 | 3499 | 0.430 |
Why?
|
| Phrenic Nerve | 1 | 2013 | 79 | 0.430 |
Why?
|
| Respiratory Paralysis | 1 | 2013 | 32 | 0.430 |
Why?
|
| Connective Tissue | 1 | 2015 | 419 | 0.430 |
Why?
|
| Thoracoscopy | 11 | 2005 | 183 | 0.430 |
Why?
|
| Chick Embryo | 2 | 2014 | 977 | 0.420 |
Why?
|
| Cell Shape | 2 | 2024 | 370 | 0.420 |
Why?
|
| Thoracic Neoplasms | 4 | 2017 | 268 | 0.410 |
Why?
|
| Macrophages, Alveolar | 2 | 2012 | 410 | 0.410 |
Why?
|
| Lung Volume Measurements | 8 | 2013 | 375 | 0.400 |
Why?
|
| Bronchi | 4 | 2022 | 843 | 0.400 |
Why?
|
| Green Fluorescent Proteins | 3 | 2013 | 2061 | 0.400 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 736 | 0.400 |
Why?
|
| Cell Movement | 8 | 2013 | 5195 | 0.390 |
Why?
|
| Diaphragm | 2 | 2013 | 351 | 0.390 |
Why?
|
| Cell Membrane Permeability | 2 | 2005 | 573 | 0.390 |
Why?
|
| Lymphatic System | 3 | 2002 | 253 | 0.380 |
Why?
|
| Extraembryonic Membranes | 1 | 2011 | 38 | 0.370 |
Why?
|
| Cytotoxicity, Immunologic | 13 | 1990 | 1351 | 0.370 |
Why?
|
| Cell Adhesion | 13 | 2019 | 3090 | 0.370 |
Why?
|
| Thoracic Wall | 4 | 2012 | 202 | 0.370 |
Why?
|
| Adjuvants, Immunologic | 5 | 2003 | 988 | 0.350 |
Why?
|
| Arginine | 4 | 2006 | 921 | 0.350 |
Why?
|
| Blood Flow Velocity | 3 | 2009 | 1374 | 0.350 |
Why?
|
| Adaptation, Physiological | 3 | 2012 | 1301 | 0.350 |
Why?
|
| Video Recording | 5 | 2007 | 965 | 0.350 |
Why?
|
| Erythema | 3 | 2006 | 262 | 0.340 |
Why?
|
| Phase Transition | 2 | 2019 | 71 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2020 | 5318 | 0.330 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 528 | 0.330 |
Why?
|
| Colitis, Lymphocytic | 1 | 2009 | 23 | 0.320 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 655 | 0.320 |
Why?
|
| Cluster Analysis | 6 | 2011 | 2706 | 0.320 |
Why?
|
| Pleural Neoplasms | 9 | 2007 | 609 | 0.320 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 15 | 1996 | 379 | 0.320 |
Why?
|
| Nanoparticles | 4 | 2010 | 1959 | 0.310 |
Why?
|
| Monocytes | 8 | 2003 | 2570 | 0.310 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2022 | 918 | 0.310 |
Why?
|
| Immunoglobulins | 2 | 2006 | 851 | 0.310 |
Why?
|
| Ganciclovir | 4 | 2006 | 253 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2015 | 9001 | 0.300 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2008 | 142 | 0.300 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2006 | 614 | 0.290 |
Why?
|
| Osteomalacia | 1 | 2007 | 60 | 0.290 |
Why?
|
| Herpesvirus 4, Human | 4 | 2001 | 1076 | 0.280 |
Why?
|
| Respiration | 4 | 2022 | 1656 | 0.280 |
Why?
|
| X-Ray Microtomography | 4 | 2019 | 450 | 0.280 |
Why?
|
| Tracheal Neoplasms | 1 | 2007 | 123 | 0.280 |
Why?
|
| Cell Separation | 5 | 2016 | 1718 | 0.270 |
Why?
|
| Mucous Membrane | 1 | 2010 | 659 | 0.270 |
Why?
|
| Microscopy, Confocal | 3 | 2009 | 1967 | 0.270 |
Why?
|
| Bronchial Arteries | 2 | 2022 | 21 | 0.270 |
Why?
|
| Calcium | 1 | 2019 | 5720 | 0.270 |
Why?
|
| Biological Clocks | 1 | 2009 | 318 | 0.270 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 771 | 0.260 |
Why?
|
| Peptide Mapping | 1 | 2006 | 259 | 0.260 |
Why?
|
| Male | 100 | 2023 | 360675 | 0.260 |
Why?
|
| Ear, External | 1 | 2006 | 165 | 0.260 |
Why?
|
| Models, Biological | 6 | 2024 | 9455 | 0.260 |
Why?
|
| Bees | 1 | 2005 | 46 | 0.260 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2017 | 350 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 6 | 2001 | 1603 | 0.250 |
Why?
|
| Mesothelioma | 8 | 2004 | 807 | 0.250 |
Why?
|
| Animals, Newborn | 2 | 2024 | 2666 | 0.250 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2007 | 262 | 0.240 |
Why?
|
| Motion | 1 | 2008 | 779 | 0.240 |
Why?
|
| Carboplatin | 1 | 2007 | 793 | 0.240 |
Why?
|
| Immunophenotyping | 3 | 2006 | 1867 | 0.230 |
Why?
|
| Glycoconjugates | 2 | 1995 | 88 | 0.230 |
Why?
|
| Neoplasm Staging | 22 | 2020 | 11118 | 0.230 |
Why?
|
| Extracellular Matrix | 2 | 2023 | 1720 | 0.230 |
Why?
|
| Thoracic Diseases | 1 | 2005 | 99 | 0.230 |
Why?
|
| Positive-Pressure Respiration | 3 | 2017 | 638 | 0.210 |
Why?
|
| Abdominal Cavity | 1 | 2023 | 34 | 0.210 |
Why?
|
| Time Factors | 18 | 2016 | 39953 | 0.210 |
Why?
|
| Inflammation | 9 | 2022 | 10758 | 0.210 |
Why?
|
| Humans | 160 | 2024 | 761098 | 0.210 |
Why?
|
| Respiratory Function Tests | 8 | 2017 | 1685 | 0.200 |
Why?
|
| Sarcoidosis | 2 | 2000 | 537 | 0.200 |
Why?
|
| Finite Element Analysis | 3 | 2014 | 437 | 0.200 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 18217 | 0.200 |
Why?
|
| Thorax | 3 | 2022 | 555 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 6 | 2020 | 2827 | 0.200 |
Why?
|
| Cell Proliferation | 5 | 2017 | 10421 | 0.200 |
Why?
|
| Trinitrobenzenesulfonic Acid | 3 | 2013 | 65 | 0.200 |
Why?
|
| Lymphocyte Activation | 10 | 1996 | 5478 | 0.200 |
Why?
|
| Thymidine Kinase | 2 | 2001 | 286 | 0.190 |
Why?
|
| Gramicidin | 1 | 2001 | 12 | 0.190 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 863 | 0.190 |
Why?
|
| Stethoscopes | 1 | 2021 | 30 | 0.190 |
Why?
|
| Thymus Gland | 2 | 2009 | 1243 | 0.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2022 | 447 | 0.190 |
Why?
|
| Blood Platelets | 2 | 2009 | 2477 | 0.190 |
Why?
|
| Oxazoles | 1 | 2002 | 199 | 0.190 |
Why?
|
| T-Lymphocytes | 9 | 2012 | 10203 | 0.190 |
Why?
|
| Models, Anatomic | 2 | 2017 | 684 | 0.190 |
Why?
|
| Oxygen | 3 | 2011 | 4226 | 0.190 |
Why?
|
| Fixatives | 1 | 2001 | 90 | 0.190 |
Why?
|
| Chickens | 1 | 2023 | 857 | 0.190 |
Why?
|
| Dermatitis, Contact | 1 | 2001 | 133 | 0.190 |
Why?
|
| Mediastinoscopy | 2 | 1997 | 29 | 0.190 |
Why?
|
| Computer Simulation | 4 | 2024 | 6225 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2020 | 9278 | 0.180 |
Why?
|
| Gels | 2 | 2020 | 420 | 0.180 |
Why?
|
| Computer Graphics | 1 | 2003 | 338 | 0.180 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 876 | 0.180 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2001 | 89 | 0.180 |
Why?
|
| Cytotoxins | 1 | 2001 | 153 | 0.180 |
Why?
|
| Nanotechnology | 1 | 2006 | 713 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 3 | 2017 | 1585 | 0.180 |
Why?
|
| Myelopoiesis | 1 | 2021 | 134 | 0.180 |
Why?
|
| Dextran Sulfate | 3 | 2013 | 258 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 1 | 2001 | 232 | 0.180 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2020 | 86 | 0.180 |
Why?
|
| Respiratory Rate | 1 | 2021 | 176 | 0.180 |
Why?
|
| Microvilli | 1 | 2020 | 234 | 0.170 |
Why?
|
| Phantoms, Imaging | 1 | 2009 | 2515 | 0.170 |
Why?
|
| Multiple Trauma | 1 | 2023 | 369 | 0.170 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2020 | 24 | 0.170 |
Why?
|
| Rats | 5 | 2024 | 23713 | 0.170 |
Why?
|
| Aldehydes | 1 | 2001 | 170 | 0.170 |
Why?
|
| Surgical Stapling | 1 | 2020 | 98 | 0.170 |
Why?
|
| Pneumonia, Viral | 4 | 2022 | 3216 | 0.170 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 660 | 0.170 |
Why?
|
| Glass | 1 | 2020 | 115 | 0.170 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2001 | 433 | 0.170 |
Why?
|
| Lymph Nodes | 9 | 2009 | 3461 | 0.170 |
Why?
|
| Thoracotomy | 6 | 1997 | 366 | 0.170 |
Why?
|
| Preoperative Care | 3 | 2007 | 2242 | 0.170 |
Why?
|
| Abdominal Injuries | 1 | 2023 | 360 | 0.170 |
Why?
|
| Cattle | 3 | 2023 | 3819 | 0.170 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 716 | 0.170 |
Why?
|
| Vitrification | 1 | 2019 | 51 | 0.160 |
Why?
|
| Drug Eruptions | 1 | 2002 | 335 | 0.160 |
Why?
|
| Coloring Agents | 3 | 2009 | 562 | 0.160 |
Why?
|
| Sus scrofa | 1 | 2020 | 428 | 0.160 |
Why?
|
| Patient Selection | 4 | 2007 | 4245 | 0.160 |
Why?
|
| Organogenesis | 2 | 2017 | 214 | 0.160 |
Why?
|
| Extracellular Fluid | 2 | 2017 | 165 | 0.160 |
Why?
|
| Ear | 4 | 2007 | 172 | 0.160 |
Why?
|
| Stem Cells | 1 | 2011 | 3512 | 0.150 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3094 | 0.150 |
Why?
|
| Chest Tubes | 2 | 2023 | 152 | 0.150 |
Why?
|
| Air Pressure | 1 | 2018 | 74 | 0.150 |
Why?
|
| Phenotype | 9 | 2017 | 16572 | 0.150 |
Why?
|
| Combined Modality Therapy | 18 | 2020 | 8519 | 0.150 |
Why?
|
| Diffusion | 1 | 2020 | 813 | 0.150 |
Why?
|
| Synchrotrons | 2 | 2015 | 39 | 0.150 |
Why?
|
| Endothelium | 3 | 2000 | 763 | 0.150 |
Why?
|
| Antigens | 2 | 2001 | 1441 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2001 | 530 | 0.150 |
Why?
|
| Transcription, Genetic | 5 | 2016 | 7574 | 0.150 |
Why?
|
| Hydrostatic Pressure | 1 | 2017 | 98 | 0.150 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2003 | 890 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2017 | 4060 | 0.140 |
Why?
|
| Sarcoma | 4 | 2017 | 1800 | 0.140 |
Why?
|
| Survival Rate | 19 | 2020 | 12727 | 0.140 |
Why?
|
| Dyspnea | 1 | 2005 | 1347 | 0.140 |
Why?
|
| Carbocyanines | 2 | 2009 | 175 | 0.140 |
Why?
|
| Haptens | 2 | 2007 | 163 | 0.140 |
Why?
|
| Organ Size | 2 | 2012 | 2253 | 0.140 |
Why?
|
| Immunoglobulin Isotypes | 2 | 1994 | 158 | 0.140 |
Why?
|
| Pneumonia | 2 | 2017 | 2142 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2001 | 1372 | 0.140 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 1996 | 25 | 0.140 |
Why?
|
| Thrombosis | 2 | 2021 | 2944 | 0.140 |
Why?
|
| Image Cytometry | 1 | 2016 | 53 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 1 | 1998 | 227 | 0.140 |
Why?
|
| HLA Antigens | 8 | 1995 | 1331 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 10 | 2001 | 6123 | 0.130 |
Why?
|
| Tomography | 2 | 2015 | 411 | 0.130 |
Why?
|
| Algorithms | 8 | 2016 | 14023 | 0.130 |
Why?
|
| Respiration, Artificial | 3 | 2017 | 2630 | 0.130 |
Why?
|
| Lectins | 2 | 1995 | 489 | 0.130 |
Why?
|
| L-Selectin | 1 | 1996 | 212 | 0.130 |
Why?
|
| Models, Cardiovascular | 2 | 2014 | 983 | 0.130 |
Why?
|
| Surface Tension | 1 | 2015 | 43 | 0.120 |
Why?
|
| Fluoroimmunoassay | 1 | 1995 | 30 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 9518 | 0.120 |
Why?
|
| Cornea | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Staining and Labeling | 2 | 2010 | 1081 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2016 | 11505 | 0.120 |
Why?
|
| Chemokines | 2 | 2009 | 956 | 0.120 |
Why?
|
| Rats, Wistar | 2 | 2017 | 1850 | 0.120 |
Why?
|
| Endothelins | 1 | 1995 | 127 | 0.120 |
Why?
|
| Cell Fusion | 2 | 2009 | 294 | 0.120 |
Why?
|
| Myocarditis | 1 | 2022 | 792 | 0.120 |
Why?
|
| Thoracic Surgery | 3 | 1996 | 722 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 6067 | 0.120 |
Why?
|
| Membrane Glycoproteins | 2 | 2020 | 3696 | 0.120 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2017 | 141 | 0.120 |
Why?
|
| o-Phthalaldehyde | 1 | 1994 | 15 | 0.120 |
Why?
|
| Situs Inversus | 1 | 1994 | 63 | 0.120 |
Why?
|
| Female | 77 | 2020 | 392458 | 0.120 |
Why?
|
| Cell Count | 3 | 2012 | 1831 | 0.120 |
Why?
|
| Total Lung Capacity | 3 | 2011 | 148 | 0.120 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.110 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1994 | 87 | 0.110 |
Why?
|
| Indoles | 2 | 2017 | 1830 | 0.110 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 1989 | 897 | 0.110 |
Why?
|
| Cell Membrane | 4 | 2003 | 3665 | 0.110 |
Why?
|
| Gene Expression Regulation | 4 | 2013 | 11856 | 0.110 |
Why?
|
| Cells, Cultured | 14 | 2006 | 18926 | 0.110 |
Why?
|
| Cell Aggregation | 3 | 1995 | 238 | 0.110 |
Why?
|
| Phosphines | 1 | 2013 | 18 | 0.110 |
Why?
|
| Indicators and Reagents | 1 | 1994 | 453 | 0.110 |
Why?
|
| Postoperative Complications | 12 | 2023 | 15634 | 0.110 |
Why?
|
| Surgical Staplers | 2 | 1997 | 34 | 0.110 |
Why?
|
| Esophageal Neoplasms | 3 | 2016 | 1658 | 0.110 |
Why?
|
| Liver | 3 | 2020 | 7513 | 0.110 |
Why?
|
| Adult | 59 | 2022 | 221083 | 0.110 |
Why?
|
| Killer Cells, Natural | 5 | 1995 | 2194 | 0.110 |
Why?
|
| Middle Aged | 64 | 2022 | 220835 | 0.100 |
Why?
|
| Thoracostomy | 1 | 2013 | 74 | 0.100 |
Why?
|
| Electrophoresis | 1 | 1993 | 225 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 1990 | 1553 | 0.100 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 1992 | 41 | 0.100 |
Why?
|
| Aged | 58 | 2022 | 169266 | 0.100 |
Why?
|
| Antiviral Agents | 3 | 2001 | 3048 | 0.100 |
Why?
|
| Cefazolin | 1 | 2013 | 94 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 8164 | 0.100 |
Why?
|
| Body Patterning | 1 | 2017 | 633 | 0.100 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1995 | 618 | 0.100 |
Why?
|
| Rheology | 2 | 2008 | 347 | 0.100 |
Why?
|
| Bronchoscopy | 4 | 2005 | 909 | 0.100 |
Why?
|
| Adenocarcinoma | 5 | 2017 | 6340 | 0.100 |
Why?
|
| Cell Size | 2 | 2005 | 625 | 0.100 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2012 | 129 | 0.100 |
Why?
|
| Eosine Yellowish-(YS) | 2 | 2002 | 69 | 0.100 |
Why?
|
| Leukocytes | 3 | 2013 | 2024 | 0.100 |
Why?
|
| Pandemics | 3 | 2020 | 8663 | 0.100 |
Why?
|
| Emphysema | 2 | 2007 | 238 | 0.100 |
Why?
|
| Biotin | 1 | 1993 | 251 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 2 | 2009 | 993 | 0.100 |
Why?
|
| Electric Conductivity | 1 | 2012 | 405 | 0.100 |
Why?
|
| Cell Line | 16 | 2001 | 15542 | 0.100 |
Why?
|
| Statistical Distributions | 2 | 2002 | 63 | 0.100 |
Why?
|
| Apoptosis | 2 | 2005 | 9478 | 0.100 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 433 | 0.100 |
Why?
|
| Information Theory | 2 | 2002 | 49 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 1994 | 401 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2017 | 514 | 0.090 |
Why?
|
| Fluoresceins | 3 | 2001 | 235 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 6 | 2003 | 2468 | 0.090 |
Why?
|
| Palliative Care | 2 | 2005 | 3593 | 0.090 |
Why?
|
| Blood Cells | 1 | 2013 | 306 | 0.090 |
Why?
|
| Tensile Strength | 2 | 2011 | 330 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 1 | 1993 | 420 | 0.090 |
Why?
|
| B-Lymphocytes | 6 | 2001 | 4744 | 0.090 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 1996 | 1348 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 753 | 0.090 |
Why?
|
| Elasticity | 1 | 2012 | 655 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 20600 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2016 | 11732 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2021 | 1002 | 0.090 |
Why?
|
| Cancer Vaccines | 3 | 2003 | 1038 | 0.090 |
Why?
|
| Periodicity | 1 | 2011 | 347 | 0.080 |
Why?
|
| Pericardial Effusion | 2 | 2005 | 247 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 637 | 0.080 |
Why?
|
| Dendritic Cells | 2 | 2000 | 2726 | 0.080 |
Why?
|
| Actins | 1 | 2016 | 2046 | 0.080 |
Why?
|
| Intussusception | 1 | 2010 | 115 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2001 | 8529 | 0.080 |
Why?
|
| Leiomyosarcoma | 1 | 1993 | 422 | 0.080 |
Why?
|
| Peptides | 1 | 2001 | 4353 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2011 | 2926 | 0.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1998 | 1549 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 558 | 0.080 |
Why?
|
| Shear Strength | 1 | 2009 | 160 | 0.080 |
Why?
|
| Tidal Volume | 1 | 2011 | 488 | 0.080 |
Why?
|
| Deltaretrovirus Infections | 1 | 1988 | 25 | 0.080 |
Why?
|
| Antigens, Differentiation | 2 | 1988 | 918 | 0.080 |
Why?
|
| Aspergillosis | 2 | 2003 | 242 | 0.080 |
Why?
|
| Lung Diseases, Obstructive | 2 | 2001 | 308 | 0.080 |
Why?
|
| Prognosis | 12 | 2017 | 29672 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2012 | 1818 | 0.080 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2011 | 156 | 0.080 |
Why?
|
| Deltaretrovirus | 1 | 1988 | 162 | 0.080 |
Why?
|
| Epidermis | 1 | 2011 | 526 | 0.080 |
Why?
|
| Forced Expiratory Volume | 6 | 2005 | 1813 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 1435 | 0.080 |
Why?
|
| Lymphoma | 4 | 2006 | 1898 | 0.080 |
Why?
|
| Ethics, Medical | 1 | 1994 | 786 | 0.080 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2004 | 279 | 0.080 |
Why?
|
| Survival Analysis | 11 | 2009 | 10083 | 0.080 |
Why?
|
| Membrane Proteins | 5 | 2021 | 7844 | 0.080 |
Why?
|
| Abdominal Neoplasms | 2 | 1997 | 287 | 0.080 |
Why?
|
| Silicon Dioxide | 1 | 2009 | 216 | 0.070 |
Why?
|
| Myocardium | 1 | 2020 | 4746 | 0.070 |
Why?
|
| Polystyrenes | 1 | 2007 | 104 | 0.070 |
Why?
|
| Picrates | 1 | 2007 | 13 | 0.070 |
Why?
|
| Hemorheology | 1 | 2007 | 144 | 0.070 |
Why?
|
| Acute Disease | 2 | 2009 | 7240 | 0.070 |
Why?
|
| Platelet Adhesiveness | 1 | 2007 | 154 | 0.070 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1988 | 818 | 0.070 |
Why?
|
| Picryl Chloride | 1 | 2006 | 9 | 0.070 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2007 | 20 | 0.070 |
Why?
|
| Fluorescence | 2 | 2007 | 754 | 0.070 |
Why?
|
| Pleural Effusion | 2 | 2005 | 341 | 0.070 |
Why?
|
| Epitopes | 5 | 1989 | 2503 | 0.070 |
Why?
|
| Software | 4 | 2011 | 4433 | 0.070 |
Why?
|
| Receptors, Immunologic | 2 | 1990 | 1408 | 0.070 |
Why?
|
| Suture Techniques | 1 | 1992 | 768 | 0.070 |
Why?
|
| Leukemia, Myeloid | 2 | 1987 | 693 | 0.070 |
Why?
|
| Esophageal Perforation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 1990 | 731 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 320 | 0.070 |
Why?
|
| Intubation | 1 | 2007 | 139 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 311 | 0.070 |
Why?
|
| Venules | 1 | 2006 | 161 | 0.070 |
Why?
|
| Erythrocytes | 2 | 2006 | 2413 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 392 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2009 | 1784 | 0.070 |
Why?
|
| Fuzzy Logic | 1 | 2006 | 57 | 0.070 |
Why?
|
| Tissue Expansion | 1 | 2007 | 160 | 0.070 |
Why?
|
| Nonlinear Dynamics | 1 | 2009 | 492 | 0.070 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 58946 | 0.070 |
Why?
|
| Calibration | 1 | 2009 | 819 | 0.070 |
Why?
|
| Splenomegaly | 1 | 1987 | 191 | 0.070 |
Why?
|
| Sialoglycoproteins | 1 | 1987 | 315 | 0.070 |
Why?
|
| Precancerous Conditions | 2 | 2004 | 982 | 0.070 |
Why?
|
| Transfection | 5 | 1990 | 5750 | 0.070 |
Why?
|
| Spleen | 2 | 2009 | 2290 | 0.060 |
Why?
|
| Arterioles | 1 | 2006 | 250 | 0.060 |
Why?
|
| Programming Languages | 1 | 2006 | 129 | 0.060 |
Why?
|
| Antineoplastic Agents | 4 | 2006 | 13630 | 0.060 |
Why?
|
| Lymphokines | 1 | 1988 | 925 | 0.060 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1985 | 65 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 3598 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 1988 | 532 | 0.060 |
Why?
|
| Donor Selection | 1 | 2007 | 232 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 1751 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 1988 | 552 | 0.060 |
Why?
|
| Retrospective Studies | 19 | 2020 | 80673 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2016 | 2452 | 0.060 |
Why?
|
| Splenectomy | 1 | 1987 | 391 | 0.060 |
Why?
|
| Postoperative Care | 3 | 2013 | 1469 | 0.060 |
Why?
|
| RNA, Messenger | 5 | 2011 | 12743 | 0.060 |
Why?
|
| Biophysics | 1 | 2006 | 379 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 1989 | 2549 | 0.060 |
Why?
|
| Membranes | 2 | 1995 | 164 | 0.060 |
Why?
|
| Paracentesis | 1 | 2005 | 98 | 0.060 |
Why?
|
| Hybrid Cells | 2 | 2000 | 421 | 0.060 |
Why?
|
| Infusions, Parenteral | 1 | 1984 | 397 | 0.060 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1984 | 221 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 9416 | 0.060 |
Why?
|
| Immunohistochemistry | 5 | 2011 | 11066 | 0.060 |
Why?
|
| Spirometry | 3 | 2021 | 928 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2009 | 3512 | 0.060 |
Why?
|
| Heart | 1 | 2017 | 4431 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 2571 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2012 | 1873 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1530 | 0.060 |
Why?
|
| Histocytochemistry | 2 | 1995 | 697 | 0.060 |
Why?
|
| Gene Expression | 2 | 2012 | 7567 | 0.050 |
Why?
|
| Receptor, Insulin | 1 | 2007 | 836 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2002 | 60 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 1988 | 317 | 0.050 |
Why?
|
| Stimulation, Chemical | 1 | 2002 | 306 | 0.050 |
Why?
|
| Swine | 2 | 2023 | 5909 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 1744 | 0.050 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 39121 | 0.050 |
Why?
|
| Arteriovenous Anastomosis | 1 | 2022 | 14 | 0.050 |
Why?
|
| Transplantation Immunology | 2 | 2001 | 537 | 0.050 |
Why?
|
| Lung Diseases, Fungal | 1 | 2003 | 125 | 0.050 |
Why?
|
| Gastrostomy | 2 | 2001 | 323 | 0.050 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2022 | 110 | 0.050 |
Why?
|
| Lymphatic Metastasis | 5 | 2009 | 2913 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 5033 | 0.050 |
Why?
|
| HLA-A2 Antigen | 5 | 1990 | 209 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 1990 | 3155 | 0.050 |
Why?
|
| Sensitivity and Specificity | 6 | 2011 | 14676 | 0.050 |
Why?
|
| Neurofibroma | 1 | 1982 | 95 | 0.050 |
Why?
|
| Enzyme Induction | 2 | 2001 | 452 | 0.050 |
Why?
|
| Trypan Blue | 1 | 2001 | 22 | 0.050 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 571 | 0.050 |
Why?
|
| Hamartoma | 2 | 1995 | 236 | 0.050 |
Why?
|
| Mesoderm | 4 | 1995 | 673 | 0.050 |
Why?
|
| Injections, Intradermal | 1 | 2001 | 116 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1995 | 1731 | 0.050 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2001 | 75 | 0.050 |
Why?
|
| Cell Communication | 6 | 1988 | 1650 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1885 | 0.050 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2000 | 213 | 0.050 |
Why?
|
| Clone Cells | 4 | 1990 | 1667 | 0.050 |
Why?
|
| Binding, Competitive | 4 | 1986 | 1139 | 0.050 |
Why?
|
| Thigh | 1 | 1982 | 239 | 0.050 |
Why?
|
| Magnetics | 2 | 1995 | 598 | 0.050 |
Why?
|
| Rhodamines | 1 | 2001 | 178 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2002 | 411 | 0.040 |
Why?
|
| Esophagectomy | 2 | 2001 | 469 | 0.040 |
Why?
|
| Haplorhini | 2 | 1995 | 523 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 1988 | 1984 | 0.040 |
Why?
|
| Doxorubicin | 3 | 1998 | 2224 | 0.040 |
Why?
|
| Mediastinum | 3 | 2001 | 267 | 0.040 |
Why?
|
| Antigens, CD | 2 | 1990 | 4008 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2001 | 153 | 0.040 |
Why?
|
| Mice, Inbred AKR | 1 | 2000 | 104 | 0.040 |
Why?
|
| Weight Loss | 1 | 2012 | 2680 | 0.040 |
Why?
|
| Jugular Veins | 1 | 2001 | 210 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2021 | 3493 | 0.040 |
Why?
|
| Treatment Outcome | 18 | 2009 | 64670 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2001 | 241 | 0.040 |
Why?
|
| Anesthesia | 1 | 2011 | 1591 | 0.040 |
Why?
|
| Esophageal Stenosis | 1 | 2001 | 197 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2003 | 355 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2003 | 2410 | 0.040 |
Why?
|
| Wound Healing | 1 | 2011 | 2801 | 0.040 |
Why?
|
| Stochastic Processes | 1 | 2001 | 355 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2001 | 357 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1986 | 926 | 0.040 |
Why?
|
| Plasmacytoma | 1 | 2000 | 170 | 0.040 |
Why?
|
| Lung Diseases | 4 | 1998 | 1909 | 0.040 |
Why?
|
| Rats, Inbred Lew | 1 | 2001 | 1159 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 426 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2007 | 1398 | 0.040 |
Why?
|
| Species Specificity | 4 | 1995 | 2406 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2021 | 588 | 0.040 |
Why?
|
| Endoscopy | 2 | 2001 | 1852 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1996 | 1250 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2691 | 0.040 |
Why?
|
| Risk Factors | 8 | 2017 | 74219 | 0.040 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 1999 | 189 | 0.040 |
Why?
|
| Lymph Node Excision | 2 | 2001 | 1269 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 781 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2001 | 713 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4565 | 0.040 |
Why?
|
| Virus Latency | 1 | 2001 | 354 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2024 | 748 | 0.040 |
Why?
|
| Melanoma | 4 | 2003 | 5694 | 0.040 |
Why?
|
| Antibodies | 1 | 2006 | 2415 | 0.040 |
Why?
|
| Mechanical Phenomena | 1 | 2019 | 142 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2003 | 838 | 0.040 |
Why?
|
| Culture Media | 2 | 1992 | 894 | 0.040 |
Why?
|
| Neoplasm Metastasis | 4 | 2009 | 4908 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2019 | 590 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2001 | 492 | 0.040 |
Why?
|
| Cisplatin | 4 | 2016 | 1651 | 0.040 |
Why?
|
| Muscles | 1 | 1982 | 1567 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 677 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2021 | 702 | 0.040 |
Why?
|
| Radiation Pneumonitis | 1 | 1998 | 102 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 6817 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2023 | 1207 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 4849 | 0.030 |
Why?
|
| Eosinophils | 2 | 1998 | 951 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2006 | 6343 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 2562 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 1997 | 106 | 0.030 |
Why?
|
| Autopsy | 1 | 2020 | 1010 | 0.030 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 1996 | 45 | 0.030 |
Why?
|
| Surface Properties | 1 | 2019 | 1162 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2004 | 2820 | 0.030 |
Why?
|
| Pulmonary Artery | 2 | 2017 | 1927 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 494 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1997 | 290 | 0.030 |
Why?
|
| Anorexia | 1 | 2016 | 153 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 6305 | 0.030 |
Why?
|
| Vincristine | 1 | 1998 | 1036 | 0.030 |
Why?
|
| Cytokines | 2 | 2009 | 7386 | 0.030 |
Why?
|
| Videotape Recording | 1 | 1997 | 336 | 0.030 |
Why?
|
| Mammals | 1 | 2001 | 1131 | 0.030 |
Why?
|
| Laryngeal Masks | 1 | 1996 | 102 | 0.030 |
Why?
|
| Neoplasms | 5 | 1997 | 22125 | 0.030 |
Why?
|
| HLA-B7 Antigen | 4 | 1990 | 48 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2006 | 5971 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2051 | 0.030 |
Why?
|
| Galactosides | 1 | 1995 | 54 | 0.030 |
Why?
|
| Empyema | 1 | 1995 | 41 | 0.030 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1995 | 46 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 29872 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2001 | 4021 | 0.030 |
Why?
|
| Goats | 1 | 1995 | 165 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2016 | 132 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 1995 | 129 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 272 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1996 | 526 | 0.030 |
Why?
|
| Attitude | 1 | 1979 | 772 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1998 | 2219 | 0.030 |
Why?
|
| Respiratory Muscles | 2 | 2007 | 142 | 0.030 |
Why?
|
| Microchemistry | 1 | 1994 | 54 | 0.030 |
Why?
|
| Leukemia | 1 | 2003 | 1518 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 1996 | 320 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 7405 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1994 | 199 | 0.030 |
Why?
|
| Genes, MHC Class I | 1 | 1995 | 235 | 0.030 |
Why?
|
| Carbohydrate Sequence | 1 | 1994 | 411 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2003 | 1670 | 0.030 |
Why?
|
| Esophagogastric Junction | 1 | 2016 | 347 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1998 | 1756 | 0.030 |
Why?
|
| Incidence | 5 | 2020 | 21357 | 0.030 |
Why?
|
| Drug Stability | 1 | 1994 | 288 | 0.030 |
Why?
|
| Cell Division | 1 | 2001 | 4451 | 0.030 |
Why?
|
| Necrosis | 1 | 1998 | 1611 | 0.030 |
Why?
|
| Vagotomy, Truncal | 1 | 1993 | 9 | 0.030 |
Why?
|
| Polymers | 1 | 2001 | 1617 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2420 | 0.030 |
Why?
|
| Papain | 2 | 2005 | 65 | 0.030 |
Why?
|
| Peptic Ulcer Perforation | 1 | 1993 | 22 | 0.030 |
Why?
|
| Solutions | 1 | 1994 | 410 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1994 | 525 | 0.030 |
Why?
|
| Prednisone | 1 | 1998 | 1565 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 10755 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1998 | 1837 | 0.030 |
Why?
|
| Adolescent | 11 | 2020 | 88271 | 0.030 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1982 | 1158 | 0.030 |
Why?
|
| Duodenal Ulcer | 1 | 1993 | 121 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 679 | 0.030 |
Why?
|
| Avidin | 1 | 1993 | 42 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 1985 | 1923 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 2855 | 0.030 |
Why?
|
| Biopsy | 2 | 2022 | 6781 | 0.030 |
Why?
|
| Vital Capacity | 3 | 2002 | 970 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 591 | 0.030 |
Why?
|
| Fibroblasts | 3 | 2016 | 4137 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 145 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 150 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2003 | 4164 | 0.030 |
Why?
|
| Amines | 1 | 1994 | 280 | 0.030 |
Why?
|
| Cholesterol | 1 | 2002 | 2902 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1993 | 212 | 0.030 |
Why?
|
| Disease Progression | 3 | 2005 | 13506 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1994 | 1057 | 0.030 |
Why?
|
| Predictive Value of Tests | 5 | 2005 | 15308 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2000 | 1662 | 0.030 |
Why?
|
| Angiography | 1 | 2017 | 1597 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1994 | 684 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 2577 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2006 | 5077 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1992 | 367 | 0.020 |
Why?
|
| Patient Advocacy | 1 | 1994 | 359 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 1703 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1231 | 0.020 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2011 | 340 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1996 | 4340 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 20120 | 0.020 |
Why?
|
| Reoperation | 3 | 2001 | 4304 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3210 | 0.020 |
Why?
|
| Liposomes | 1 | 1995 | 783 | 0.020 |
Why?
|
| Granulation Tissue | 1 | 2011 | 92 | 0.020 |
Why?
|
| HLA-D Antigens | 2 | 1988 | 130 | 0.020 |
Why?
|
| Temperature | 2 | 1989 | 2219 | 0.020 |
Why?
|
| Alginates | 1 | 1992 | 248 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1998 | 1498 | 0.020 |
Why?
|
| Occlusive Dressings | 1 | 2011 | 52 | 0.020 |
Why?
|
| Perfusion | 1 | 1996 | 1390 | 0.020 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1990 | 53 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 1988 | 1891 | 0.020 |
Why?
|
| Health Priorities | 1 | 1994 | 375 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1992 | 218 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 978 | 0.020 |
Why?
|
| Lipids | 1 | 2002 | 3330 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1994 | 4538 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 1994 | 435 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 627 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 1624 | 0.020 |
Why?
|
| Cells | 1 | 2011 | 164 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1985 | 4240 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1989 | 445 | 0.020 |
Why?
|
| Maximal Expiratory Flow-Volume Curves | 2 | 1999 | 25 | 0.020 |
Why?
|
| Haplotypes | 1 | 1996 | 2714 | 0.020 |
Why?
|
| Genetic Engineering | 3 | 2003 | 929 | 0.020 |
Why?
|
| Disabled Persons | 1 | 1979 | 1226 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2007 | 12467 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2278 | 0.020 |
Why?
|
| Child, Preschool | 4 | 2022 | 42217 | 0.020 |
Why?
|
| Safety | 3 | 1999 | 1151 | 0.020 |
Why?
|
| Treatment Failure | 3 | 2005 | 2643 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 1996 | 3591 | 0.020 |
Why?
|
| Radiography | 2 | 2007 | 6975 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1995 | 1140 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1996 | 2195 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1527 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 36418 | 0.020 |
Why?
|
| Length of Stay | 5 | 2007 | 6420 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1990 | 282 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2020 | 1521 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2873 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 2005 | 12058 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 4372 | 0.020 |
Why?
|
| Collagen | 1 | 2017 | 2635 | 0.020 |
Why?
|
| Solubility | 1 | 1990 | 1085 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1988 | 218 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 4014 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2003 | 3200 | 0.020 |
Why?
|
| Smoking | 3 | 1999 | 9055 | 0.020 |
Why?
|
| Splenic Neoplasms | 1 | 1988 | 94 | 0.020 |
Why?
|
| Abdomen | 2 | 2001 | 1128 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 4574 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 1125 | 0.020 |
Why?
|
| Barium | 1 | 2007 | 62 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1990 | 544 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2007 | 148 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 197 | 0.020 |
Why?
|
| Delayed Graft Function | 1 | 2007 | 53 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 2393 | 0.020 |
Why?
|
| Proteins | 1 | 2002 | 5993 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1988 | 564 | 0.020 |
Why?
|
| Karnofsky Performance Status | 2 | 1998 | 166 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1987 | 131 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2000 | 4479 | 0.020 |
Why?
|
| Leukemia, Experimental | 1 | 1986 | 225 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 2 | 2000 | 828 | 0.020 |
Why?
|
| Young Adult | 3 | 2020 | 59199 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 2112 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 1986 | 97 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1996 | 2247 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 1992 | 743 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2017 | 9317 | 0.020 |
Why?
|
| Infant | 2 | 2022 | 36164 | 0.020 |
Why?
|
| Prospective Studies | 8 | 2013 | 54419 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2007 | 267 | 0.020 |
Why?
|
| Fluorescein | 1 | 1986 | 175 | 0.020 |
Why?
|
| Hematocrit | 1 | 1987 | 623 | 0.020 |
Why?
|
| Linear Models | 3 | 2001 | 5869 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1987 | 509 | 0.020 |
Why?
|
| Kinetics | 3 | 2007 | 6312 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 1987 | 602 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1985 | 359 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2007 | 557 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 1996 | 20981 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 12975 | 0.020 |
Why?
|
| Manometry | 1 | 2007 | 453 | 0.010 |
Why?
|
| Penis | 1 | 1986 | 212 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1988 | 333 | 0.010 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2007 | 380 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6224 | 0.010 |
Why?
|
| Child | 4 | 2022 | 80134 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 3368 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1987 | 1429 | 0.010 |
Why?
|
| Collagen Type I | 1 | 2007 | 616 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1986 | 976 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1994 | 2334 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2001 | 8000 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 9025 | 0.010 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2003 | 45 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1987 | 2262 | 0.010 |
Why?
|
| Residual Volume | 1 | 2002 | 40 | 0.010 |
Why?
|
| Rhabdomyosarcoma | 2 | 1984 | 358 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1450 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 1240 | 0.010 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1982 | 64 | 0.010 |
Why?
|
| Methods | 1 | 1982 | 1063 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1985 | 548 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 17598 | 0.010 |
Why?
|
| Immunosuppressive Agents | 2 | 2000 | 4189 | 0.010 |
Why?
|
| Jejunostomy | 1 | 2001 | 59 | 0.010 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2001 | 66 | 0.010 |
Why?
|
| Health Policy | 1 | 1994 | 2680 | 0.010 |
Why?
|
| Esophageal Fistula | 1 | 2001 | 60 | 0.010 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2001 | 117 | 0.010 |
Why?
|
| Neutrophils | 1 | 1993 | 3763 | 0.010 |
Why?
|
| Esophagus | 1 | 2007 | 1033 | 0.010 |
Why?
|
| Sarcoma, Synovial | 1 | 1982 | 153 | 0.010 |
Why?
|
| Neutropenia | 1 | 1986 | 885 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1988 | 955 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 1994 | 3238 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2001 | 368 | 0.010 |
Why?
|
| Normal Distribution | 1 | 2001 | 272 | 0.010 |
Why?
|
| Inspiratory Capacity | 1 | 1999 | 35 | 0.010 |
Why?
|
| Dilatation | 1 | 2001 | 307 | 0.010 |
Why?
|
| Decision Trees | 1 | 2002 | 505 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1988 | 2839 | 0.010 |
Why?
|
| Retinal Vessels | 1 | 2005 | 854 | 0.010 |
Why?
|
| Asthma | 1 | 1998 | 6229 | 0.010 |
Why?
|
| Plethysmography | 1 | 1999 | 174 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1084 | 0.010 |
Why?
|
| Catheterization | 1 | 1984 | 1428 | 0.010 |
Why?
|
| Pressure | 1 | 2002 | 1152 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1624 | 0.010 |
Why?
|
| Tumor Virus Infections | 1 | 1982 | 435 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2013 | 12341 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 3509 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2478 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1999 | 228 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 2443 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1987 | 2117 | 0.010 |
Why?
|
| Research Design | 1 | 1994 | 6178 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1986 | 4612 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1999 | 473 | 0.010 |
Why?
|
| Self Care | 1 | 2003 | 795 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 1200 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2002 | 1636 | 0.010 |
Why?
|
| Bronchitis | 1 | 1998 | 196 | 0.010 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1998 | 112 | 0.010 |
Why?
|
| Sclerosing Solutions | 1 | 1997 | 79 | 0.010 |
Why?
|
| Esophagoscopy | 1 | 1999 | 398 | 0.010 |
Why?
|
| Chromosome Aberrations | 2 | 1995 | 1767 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2001 | 947 | 0.010 |
Why?
|
| Quality of Life | 1 | 1999 | 13362 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2001 | 573 | 0.010 |
Why?
|
| Pericardial Window Techniques | 1 | 1996 | 10 | 0.010 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 1999 | 285 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2001 | 1989 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1982 | 1225 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 138 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3803 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 2003 | 922 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2001 | 491 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1986 | 2911 | 0.010 |
Why?
|
| Leucovorin | 1 | 1997 | 643 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1995 | 260 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2002 | 1723 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 3594 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 2001 | 14607 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 1995 | 137 | 0.010 |
Why?
|
| Mutation | 2 | 1989 | 30006 | 0.010 |
Why?
|
| ROC Curve | 1 | 2002 | 3582 | 0.010 |
Why?
|
| Choice Behavior | 1 | 1979 | 824 | 0.010 |
Why?
|
| Disease Management | 1 | 2004 | 2508 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 1999 | 970 | 0.010 |
Why?
|
| Pyloric Antrum | 1 | 1993 | 66 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2004 | 41486 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2005 | 24013 | 0.010 |
Why?
|
| Leukemia, T-Cell | 1 | 1993 | 101 | 0.010 |
Why?
|
| Lipoma | 1 | 1995 | 293 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1998 | 1089 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1992 | 26187 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1992 | 247 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1992 | 286 | 0.010 |
Why?
|
| Drainage | 1 | 1997 | 1158 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1992 | 410 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9324 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1993 | 656 | 0.010 |
Why?
|
| Sepsis | 1 | 1985 | 2586 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1992 | 430 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2001 | 2682 | 0.010 |
Why?
|
| Protein Conformation | 2 | 1989 | 3936 | 0.010 |
Why?
|
| Age Factors | 2 | 1999 | 18385 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 4822 | 0.010 |
Why?
|
| Karyotyping | 1 | 1992 | 1171 | 0.010 |
Why?
|
| Pain | 1 | 1986 | 5070 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 1750 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1993 | 691 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1997 | 2359 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1990 | 176 | 0.010 |
Why?
|
| Leiomyoma | 1 | 1995 | 636 | 0.010 |
Why?
|
| Motivation | 1 | 1979 | 2003 | 0.010 |
Why?
|
| Carcinoma | 1 | 2001 | 2328 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 9300 | 0.010 |
Why?
|
| Esterases | 1 | 1989 | 88 | 0.010 |
Why?
|
| Attention | 1 | 1979 | 2394 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 1989 | 104 | 0.010 |
Why?
|
| Cystic Fibrosis | 1 | 1998 | 1283 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1984 | 4308 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 5494 | 0.000 |
Why?
|
| Health Care Costs | 1 | 2002 | 3238 | 0.000 |
Why?
|
| Intubation, Intratracheal | 1 | 1996 | 1331 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1988 | 812 | 0.000 |
Why?
|
| Tunicamycin | 1 | 1987 | 108 | 0.000 |
Why?
|
| Transformation, Genetic | 1 | 1987 | 192 | 0.000 |
Why?
|
| Isoantigens | 1 | 1989 | 559 | 0.000 |
Why?
|
| H-2 Antigens | 1 | 1987 | 358 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1990 | 23415 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1992 | 1391 | 0.000 |
Why?
|
| Major Histocompatibility Complex | 1 | 1989 | 872 | 0.000 |
Why?
|
| Pericardium | 1 | 1991 | 674 | 0.000 |
Why?
|
| United States | 2 | 2007 | 72337 | 0.000 |
Why?
|
| Aotus trivirgatus | 1 | 1986 | 36 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1993 | 1866 | 0.000 |
Why?
|
| Growth Substances | 1 | 1988 | 759 | 0.000 |
Why?
|
| Uterine Neoplasms | 1 | 1995 | 1420 | 0.000 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1988 | 629 | 0.000 |
Why?
|
| Receptors, Fc | 1 | 1989 | 536 | 0.000 |
Why?
|
| Exercise Test | 1 | 1993 | 2165 | 0.000 |
Why?
|
| Binding Sites | 1 | 1993 | 5993 | 0.000 |
Why?
|
| Macrophage-1 Antigen | 1 | 1985 | 286 | 0.000 |
Why?
|
| Anxiety | 1 | 1979 | 4572 | 0.000 |
Why?
|
| Oligonucleotides | 1 | 1987 | 563 | 0.000 |
Why?
|
| Glycosylation | 1 | 1987 | 1095 | 0.000 |
Why?
|
| Myocardial Infarction | 1 | 1985 | 11475 | 0.000 |
Why?
|
| Macrophages | 1 | 1998 | 5754 | 0.000 |
Why?
|
| Tampons, Surgical | 1 | 1982 | 10 | 0.000 |
Why?
|
| Moloney murine leukemia virus | 1 | 1982 | 109 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1982 | 249 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1997 | 4642 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1988 | 2200 | 0.000 |
Why?
|
| Culture Techniques | 1 | 1980 | 531 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1989 | 5413 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1982 | 2010 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1987 | 13404 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1980 | 1963 | 0.000 |
Why?
|